FCN-159 is under clinical development by Fochon Pharmaceutical and currently in Phase II for Neurofibromatoses Type I (Von Recklinghausen’s Disease). According to GlobalData, Phase II drugs for Neurofibromatoses Type I (Von Recklinghausen’s Disease) have a 33% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how FCN-159’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
FCN-159 is under development for the treatment of solid tumors including metastatic melanoma, relapsed or advanced low-grade glioma and neurofibromatosis type 1 in adults and pediatrics. It is also under development for Langerhans cell histiocytosis (LCH), Erdheim-Chester disease (ECD), other histiocytic tumors and extracranial arteriovenous malformations. It is administered through oral route in the form of tablet. The drug candidate acts by targeting the enzyme MEK1 and MEK2.
Fochon Pharmaceutical overview
Chongqing Fochon Pharmaceutical Co., Ltd. is engaged in the research and development of chemical drugs.
For a complete picture of FCN-159’s drug-specific PTSR and LoA scores, buy the report here.